About
Pricing
FAQs
Providers
Trials
Blog
Login
Get started
Finding studies
Search
Narrow
Order
Status
Recruiting
Not yet recruiting
Active, not recruiting
Enrolling by invitation
Completed
Terminated
Phase
Early phase 1
Phase 1
Phase 1–2
Phase 2
Phase 2–3
Phase 3
Phase 4
No phase
Who can join
Healthy volunteers too
Searching
1–20 of 1,937
Completed
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select…
NCT04242199
·
Boston, Massachusetts and 20 others
Terminated
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or…
NCT06264921
·
San Francisco, California and 7 others
Recruiting
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor…
NCT05269381
·
Jacksonville, Florida
Terminated
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Study STML-901-0119 was a dose-escalation study evaluating multiple doses and schedules of orally administered SL-901 in patients with advanced solid tumors.
NCT05382936
·
Sutton, Surrey and 1 other
Active not recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with…
NCT04616534
·
Bethesda, Maryland and 2 others
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection.
NCT05477849
·
Hangzhou, Zhejiang
Unknown
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
This is a phase I/II, open-label, multi-center, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of…
NCT05278364
·
Shanghai, Shanghai Municipality and 1 other
Completed
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
The LNA-i-miR-221 Phase I trial has been designed as a monocentric open label dose escalation study which received written approval by the Competent Authority and independent…
NCT04811898
·
Catanzaro
Active not recruiting
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast…
NCT05251714
·
Columbus, Ohio and 3 others
Recruiting
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants…
NCT06759649
·
New Haven, Connecticut and 10 others
Recruiting
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and…
NCT07105215
·
Beijing, Beijing Municipality and 38 others
Completed
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
Background: Immunotherapy drugs help the body to fight cancer. Scientists think that combining some of these drugs will make them work better than when used alone.
NCT03493945
·
Bethesda, Maryland
Completed
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: * To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic…
NCT01140607
·
La Jolla, California and 13 others
Completed
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
This clinical trial evaluated the safety and potential benefits of combining two cancer treatments, tislelizumab and lenvatinib, in Chinese participants with advanced or…
NCT05014828
·
Hefei, Anhui and 12 others
Not yet recruiting
CAR-T for Claudin18.2 Positive Solid Tumors
The purpose of this clinical trial is to learn if autologous claudin18.2-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat claudin18.2 positive solid tumors…
NCT07266311
·
Chengdu, Sichuan
Completed
Study of AGEN1571 in Participants With Advanced Solid Tumors
This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of…
NCT05377528
·
Los Angeles, California and 5 others
Terminated
Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients
This Phase Ib/II study is an openlabel, multicenter study for patients with solid tumors and breast cancer amenable to anthracyclin therapy.
NCT01131364
·
Ancona and 4 others
Unknown
ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
NCT05276609
·
Beijing, Beijing Municipality
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
This is an open-label, dose-escalation and cohort expansion study to evaluate the safety and preliminary efficacy of YSCH-01 in subjects with pulmonary metastasis of advanced…
NCT07793500
·
Beijing
Terminated
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
A Phase I, open-label clinical pharmacology study designed to evaluate the effect of tipifarnib on cardiac repolarization (corrected QT interval \[QTc\] duration) following a…
NCT04865159
·
Canton, Ohio and 2 others
Back
1
2
3
···
97
1 / 97
Next
Data from
ClinicalTrials.gov
Terms
